TLR9 and cancer: The different extent dSLIM® and ProMune® express these qualities are characteristic for each of the two TLR9 agonists and are appellative even if dSLIM® and ProMune® are compared at their individual most effective concentrations (see Fig. 4): dSLIM® displays a multifaceted profile for the relevant anti‐cancer features while ProMune® performs well only for some activities with the most pronounced (induction of IL‐8 secretion) being essentially cancer promoting.